Advertisement

Die Bisphosphonattherapie der Osteoporose: Die Verhinderung der osteoporotischen Fraktur

  • A. Grauer
  • F. Raue

Zusammenfassung

Die Bisphosphonate sind eine Klasse von Arzneimitteln mit spezifisch biologischer Wirkung am Knochen. Sie vermindern den Knochenumsatz durch Hemmung des Knochenabbaus. Auf der Suche nach stabilen Analoga der natürlich vorkommenden anorganischen Pyrophosphate wurde als erster Vertreter schon vor 30 Jahren das Etidronat verwendet [15]. Inzwischen sind eine Reihe weiterer Bisphosphonate entwickelt und in großen klinischen Entwicklungsprogrammen getestet worden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D (2000) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517–525PubMedCrossRefGoogle Scholar
  2. 2.
    Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821–828PubMedCrossRefGoogle Scholar
  3. 3.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
  4. 4.
    Black DM, Thompson DE, Bauer D, Hochberg M, Ensrud K, Musliner TA, Yates J, Cummings SR (2000) The early antifracture effect of alendronate in women with osteoporosis: results from the fracture intervention trial. Bone 26(suppl):B24Google Scholar
  5. 5.
    Castell DO (1996) „Pill esophagitis“-the case of alendronate. N Engl J Med 335:1058–1059PubMedCrossRefGoogle Scholar
  6. 6.
    Chesnut CH, 3rd (1995) Tiludronate: development as an osteoporosis therapy. Bone 17:517s–519sPubMedCrossRefGoogle Scholar
  7. 7.
    Cooper C, Atkinson EJ, O’Fallon WM, Melton LJd (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221–227PubMedCrossRefGoogle Scholar
  8. 8.
    Cooper C, Hanley D, Benamou L, Valent D, Seeman E, Lindsay R (2000) Prevalent fractures predict new vertebral fractues in 1 year. Calcif Tissue Int 66(suppl. 1):P-259Google Scholar
  9. 9.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedCrossRefGoogle Scholar
  10. 10.
    de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N. Engl J Med 335:1016–1021PubMedCrossRefGoogle Scholar
  11. 11.
    Demerjian N, Bolla G, Spreux A (1999) Severe oral ulcerations induced by alendronate. Clin Rheumatol 18:349–350PubMedCrossRefGoogle Scholar
  12. 12.
    Eastell R (1998) Treatment of postmenopausal osteoporosis. N. Engl. J. Med. 338:736–746PubMedCrossRefGoogle Scholar
  13. 13.
    Felsenberg D, Lunt M, Armbrecht G, Benevolenskaja L, Bhalla A, Bruges Armas J, Cannata J, Dequeker J, Fabian CBF (1999) Rates and determinants of vertebral fracture incidence in european men and women. J Bone Min Res 14(Suppl 1):1105Google Scholar
  14. 14.
    Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, Massoni C, Cristallini S (1995) Cyclic clodronate is effective in preventing postmenopausal bone loss: A comparative Study with transcutaneous hormone replacement therapy. Bone and Min Res 10:697–703CrossRefGoogle Scholar
  15. 15.
    Fleisch H, Russell RGG, Francis MD (1969) Diphosphonates inhibit hydroxyapatit dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264PubMedCrossRefGoogle Scholar
  16. 16.
    Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster J-Y, group ftB-MS (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo controlled trial. J Clin Endocrinol Metab 85:1895–1900PubMedCrossRefGoogle Scholar
  17. 17.
    Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA (1991) Differential action of pamidronate on trabecular and cortical bone in women with involutional posteoporosis. Osteoporosis Int. 1:129–133CrossRefGoogle Scholar
  18. 18.
    Geusens P, Adami S, W. B, McClung M, Meunier P, Miller P, Reginster J-Y, Zippel H (2000) Risedronate reduces risk of hip fracture in elderly women with osteoporosis. Calcif tissue Int 66(Suppl 1):0–70Google Scholar
  19. 19.
    Giannini S, Dangelo A, Malvasi L, Castrignano R, Pati T, Tronca R, Liberto L, Nobile M, Crepaldi G (1993) Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14:137–141PubMedCrossRefGoogle Scholar
  20. 20.
    Graham DY, Malaty HM (1999) Alendronate gastric ulcers. Aliment Pharmacol Ther 13:515–519PubMedCrossRefGoogle Scholar
  21. 21.
    Grauer A, Heichel S, Knaus J, Dosch E, Ziegler R (1999) Ibandronate treatment in Paget’s disease of bone. Bone 24:87s–89sPubMedCrossRefGoogle Scholar
  22. 22.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352Google Scholar
  23. 23.
    Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Medicine 95:557–567CrossRefGoogle Scholar
  24. 24.
    Hooper M, Hanley DA, Eastell R, Boling E, Ribot C, Woodson G, I. B (2000 (in press)) Sustained effect of risedronate in the prevention of the first vertebral fracture in women. J Bone Min Res 15Google Scholar
  25. 25.
    Hosking D, Keller K, Hooper M, Stevens K, Strauss D, Adachi J (2000) Risedronate is well tolerated in postmenopaual osteoporotic women using NSAIDs or with underlying gastrintestinal disorder. Calcif Tissue Int. 66(Suppl l):P-270Google Scholar
  26. 26.
    Klaushofer K (2000) The early and consistent anti-fracture effect of alendronate in women with post-menopausal osteoporosis in the fracture-intervention trial. Calcif Tissue Int 66(Suppl l):S304Google Scholar
  27. 27.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequecker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB, Group ftOTS (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443PubMedCrossRefGoogle Scholar
  28. 28.
    Lindsay R, Watts N, Roux C, Barton I, Flowers K, Cooper C (2000) One-in-five osteoporotic women will fracture again within one year of an incident vertebral fracture. Calcif Tissue Int 66(suppl. l):0–33Google Scholar
  29. 29.
    McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan GeH, Reda C, Yates AJ, Ravn P (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group [see comments]. Ann Intern Med 128:253–261PubMedGoogle Scholar
  30. 30.
    Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross P, Jackson RD, Hoseyni MS, Schoenfeld SL, D. V, Chestnut III CH (1997) Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 103:468–476PubMedCrossRefGoogle Scholar
  31. 31.
    Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR (2000) Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 160:77–85PubMedCrossRefGoogle Scholar
  32. 32.
    Ott SM, Woodson GC, Huffer WE, Miller PD, Watts NB (1994) Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 78:968–972PubMedCrossRefGoogle Scholar
  33. 33.
    Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbagallo M, Costi D, Biondi M, Girasole G, Arlunno B, Palummeri E (1991) Intermittent treatment with intravenous 4-amino-l-hydroxybutylidene-l, 1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Min. 15:237–248CrossRefGoogle Scholar
  34. 34.
    Pecherstorfer M, Jilch R, Sauty A, Horn E, Keck AV, Zimmer Roth I, Thiebaud D (2000) Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 15:147–154PubMedCrossRefGoogle Scholar
  35. 35.
    Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz Torres M, Wilkin TJ, Qin sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9:461–468PubMedCrossRefGoogle Scholar
  36. 36.
    Raue F, Ziegler R (1996) Knochenstoffwechsel und-erkrankungen. Internist 36:539–549Google Scholar
  37. 37.
    Ravn P, Clemmesen B, Riis BJ, Christiansen C (1996) The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19:527–533PubMedCrossRefGoogle Scholar
  38. 38.
    Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumangnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with postmenopausal osteoporosis. Osteoporosis Int 11:83–91CrossRefGoogle Scholar
  39. 39.
    Reid D, Devogelaer JP, Hughes R, Laan R, Adami S, Sacco-Gibson D, Wenderoth D (1999) Risedronate is effective and well tolerated in treating corticosteroid osteoporosis. J Bone Min Res 14(Suppl 1):1623Google Scholar
  40. 40.
    Roux, Miller P, Gennari C, Keller M, Sorensen O, Ritter-Hrncirik C, Barton I, Watts N (1999) Risedronate rapidly reduces vertebral fracture risk in postmenopausal women with established osteoporosis. Arthr Rheum 42(Suppl 9):1300Google Scholar
  41. 41.
    Roux C, Wasnich R, Adachi J, Zippel H, Bos K, Fogelman I (2000) Risedronate rapidly and consistenty reduces vertebral fracture risk in elderly postmenopausal women. Osteoporos Int 11(Suppl 2):525Google Scholar
  42. 42.
    Storm T, Kollerup G, Thamsborg G, Genant HK, Sorensen OH (1996) Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 23:1560–4PubMedGoogle Scholar
  43. 43.
    Storm T, Steiniche T, Thamsborg G, Meisen F (1993) Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone, Min Res 8:199–208CrossRefGoogle Scholar
  44. 44.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sßrensen OH (1990) Effect of intermittent cyclial etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoprosis. New Engl J Med 322:1265–1271PubMedCrossRefGoogle Scholar
  45. 45.
    Thiebaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C (1994) Two years’ effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 4:76–83PubMedCrossRefGoogle Scholar
  46. 46.
    Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora II AC (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488–501PubMedCrossRefGoogle Scholar
  47. 47.
    van Staa T (1997) Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 103:462–467PubMedCrossRefGoogle Scholar
  48. 48.
    van Staa TP, Abenhaim L, Cooper C (1998) Use of cyclicyl etidronate and prevention of non-vertebral fractures. Br J Rheumatol 37:87–94PubMedCrossRefGoogle Scholar
  49. 49.
    Watts NB (1998) Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin North Am 27:419–439PubMedCrossRefGoogle Scholar
  50. 50.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson III GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chestnut III CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New Engl J Med 323:73–79PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • A. Grauer
  • F. Raue

There are no affiliations available

Personalised recommendations